Journal
FARADAY DISCUSSIONS
Volume 177, Issue -, Pages 155-161Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4fd00176a
Keywords
-
Categories
Funding
- Department of Biotechnology, Govt. of India (DBT) [BT/PR7703/27/493/2013]
Ask authors/readers for more resources
Nonhomologous end joining (NHEJ) of DNA double strand breaks (DSBs) inside cells can be selectively inhibited by 5,6-bis-(benzylideneamino)-2-mercaptopyrimidin-4-ol (SCR7) which possesses anticancer properties. The hydrophobicity of SCR7 decreases its bioavailability which is a major setback in the utilization of this compound as a therapeutic agent. In order to circumvent the drawback of SCR7, we prepared a polymer encapsulated form of SCR7. The physical interaction of SCR7 and Pluronic (R) copolymer is evident from different analytical techniques. The in vitro cytotoxicity of the drug formulations is established using the MTT assay.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available